The Medicines Company (MDCO) Given Average Rating of “Buy” by Brokerages

Shares of The Medicines Company (NASDAQ:MDCO) have earned an average rating of “Buy” from the twelve brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $52.29.

Several brokerages have recently issued reports on MDCO. Zacks Investment Research cut The Medicines from a “hold” rating to a “sell” rating in a research note on Tuesday. BidaskClub cut The Medicines from a “hold” rating to a “sell” rating in a research note on Thursday, April 5th. Oppenheimer reiterated a “buy” rating on shares of The Medicines in a research note on Thursday, March 22nd. ValuEngine upgraded The Medicines from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Finally, Jefferies Group reiterated a “buy” rating and issued a $47.00 price objective on shares of The Medicines in a research note on Friday, February 23rd.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ MDCO traded down $1.07 during mid-day trading on Thursday, hitting $30.08. The company had a trading volume of 408,945 shares, compared to its average volume of 1,391,425. The stock has a market cap of $2,227.82, a P/E ratio of -3.58 and a beta of 0.65. The company has a current ratio of 3.21, a quick ratio of 3.18 and a debt-to-equity ratio of 26.06. The Medicines has a 1-year low of $24.45 and a 1-year high of $53.39.

The Medicines (NASDAQ:MDCO) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.71). The company had revenue of $8.60 million during the quarter, compared to analyst estimates of $20.71 million. The Medicines had a negative net margin of 1,035.27% and a negative return on equity of 316.40%. The firm’s revenue was down 50.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.19) earnings per share. equities analysts forecast that The Medicines will post -2.71 EPS for the current fiscal year.

In related news, Director Armin M. Kessler sold 20,000 shares of the stock in a transaction on Monday, April 16th. The stock was sold at an average price of $28.71, for a total value of $574,200.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director William Crouse sold 7,500 shares of the stock in a transaction on Wednesday, March 21st. The shares were sold at an average price of $32.26, for a total value of $241,950.00. Following the completion of the transaction, the director now directly owns 60,633 shares in the company, valued at approximately $1,956,020.58. The disclosure for this sale can be found here. Corporate insiders own 8.22% of the company’s stock.

A number of large investors have recently bought and sold shares of MDCO. SG Americas Securities LLC purchased a new position in The Medicines in the third quarter valued at $198,000. Granahan Investment Management Inc. MA purchased a new position in The Medicines in the third quarter valued at $1,220,000. California Public Employees Retirement System increased its holdings in The Medicines by 1.3% in the third quarter. California Public Employees Retirement System now owns 159,600 shares of the company’s stock valued at $5,912,000 after buying an additional 2,000 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in The Medicines by 27.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 10,780 shares of the company’s stock valued at $295,000 after buying an additional 2,300 shares during the last quarter. Finally, Atria Investments LLC purchased a new position in The Medicines in the fourth quarter valued at $297,000.

ILLEGAL ACTIVITY WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/19/the-medicines-company-mdco-given-average-rating-of-buy-by-brokerages.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply